Treatment of systemic sclerosis: potential role for stem cell transplantation.

Authors

Wen Xiong, Division of Rheumatology, Thomas Jefferson University
Chris T Derk, Division of Rheumatology, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

11-18-2009

Comments

This article has been peer reviewed. It was published in: Stem Cells Cloning.
2009 January; 2: 1–9.
The published version is available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781687/.

Copyright © 2009 Xiong and Derk, publisher and licensee Dove Medical Press Ltd.

Abstract

Hematopoietic stem cell transplantation may "reset" the immune reconstitution and induce self tolerance of autoreactive lymphocytes, and has been explored in the treatments for systemic sclerosis. Phase I/II trials have shown a satisfactory risk benefit ratio. The true benefit will be identified by two ongoing prospective, randomized phase III trials. Multipotent mesenchymal stromal cells (MSCs) possess antiproliferative, anti-inflammatory, and immunosuppressive properties. The use of MSCs has showed successful responses in patients with severe steroid-resistant acute graft versus host disease in phase II trials, and may be a potentially promising option for patients with systemic sclerosis.

Recommended Citation

Xiong, Wen and Derk, Chris T, "Treatment of systemic sclerosis: potential role for stem cell transplantation." (2009). Division of Internal Medicine Faculty Papers & Presentations. Paper 12.
https://jdc.jefferson.edu/internalfp/12

PubMed ID

24198505